Contents

Search

phosphorylated tau in CSF

Clinical significance: - CSF p-tau more more closely with PET scan cerebral beta-amyloid than with neurofibrillary tangles [3] - N-terminal phospho-tau181 in CSF & N-terminal phospho-tau217 in CSF with concordance of 88.2%, better than mid phospho-tau181 in CSF with either N-terminal measure [2] Increases: - increases in patients with Alzheimer's disease - increases in 4th decade in patients with Down syndrome [1]

General

microtubule-associated protein tau in CSF

References

  1. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: A cross-sectional study. Lancet 2020 Jun 27; 395:1988. PMID: 32593336 Free PMC article https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30689-9/fulltext - Head E, Ances B. Biomarkers in Down syndrome can help us understand Alzheimer's disease. Lancet 2020 Jun 27; 395:1951 PMID: 32593327 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30916-8/fulltext
  2. Karikari TK et al Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. Alzheimers & Dementia 2020. Nov 30 PMID: 33252199 https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.12236
  3. Therriault J, Vermeiren M, Servaes S et al Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol. Published online December 12, 2022 PMID: 36508198 https://jamanetwork.com/journals/jamaneurology/fullarticle/2799180

Component-of

phosphorylated tau/Abeta42 in CSF